ASIT biotech

Beleggen en aandelen kopen in België, beursberichten, informatie delen, beurskoersen analyseren + Mid, Small, Fixing

beursfre
Forum verkenner
Forum verkenner
Berichten: 70
Lid geworden op: 02 mar 2018 15:26
waarderingen: 14
Contacteer:

Re: ASIT biotech

Bericht door beursfre » 13 nov 2019 22:30

And its gone! schreef:
13 nov 2019 17:53
Op een maand tijd 54% gestegen.
Vraag me af hoeveel gaan blijven zitten tot het uur van de waarheid.
ik niet volledig
heb pak (3/4) verkocht vandaag op 1,93€
verwacht toch een dalingske tot the day
en dan stap ik terug wa bij in
Asit, Biocartis, Bone, Exmar, IBA, Inventiva, Mdx



powered by Surfing Waves

Gebruikersavatar
Chukky2
Forum actieveling
Forum actieveling
Berichten: 788
Lid geworden op: 24 jun 2014 21:32
waarderingen: 145
Contacteer:

Re: ASIT biotech

Bericht door Chukky2 » 14 nov 2019 10:24

Oei oei . Handel licht stil
avantiumBamBayer-BiocartiBpost-cresent-econocom -Exmar -Fagron-greenyard-ing-MDxH-Nyrstar -Ontex -Oxurion-Pharming-umicore-XFab-Arcelor ,IAsiat-Aperam-melexis-Solvay,AMG,.galap.verk:kbc,bekaert

Gebruikersavatar
Naz-T
Forum actieveling
Forum actieveling
Berichten: 797
Lid geworden op: 06 sep 2018 20:48
waarderingen: 320
Contacteer:

Re: ASIT biotech

Bericht door Naz-T » 14 nov 2019 10:33

Chukky2 schreef:
14 nov 2019 10:24
Oei oei . Handel licht stil
:o

10:27
Handel in ASIT Biotech opgeschort
De handel in biotechbedrijf ASIT ASIT2,63% is opgeschort, meldt de beurswaakhond FSMA. Dit in afwachting van de uitkomst van de buitengewone aandeelhoudersvergadering van vandaag.

Door de opeenvolgende verliezen is het eigen vermogen immers onder de helft van het maatschappelijke startkapitaal gezakt. En dan treedt artikel 633 van de Belgische vennootschapswetgeving in werking. Zeg maar de 'alarmbelprocedure', die aandeelhouders verplicht te stemmen of ze nog willen voortdoen met een bedrijf dat intussen de helft van de initiële inleg kwijt is.
vogelspotter liked last!

Osteles
Forum verkenner
Forum verkenner
Berichten: 70
Lid geworden op: 29 aug 2016 12:29
waarderingen: 7
Contacteer:

Re: ASIT biotech

Bericht door Osteles » 14 nov 2019 10:40

Oei, dat is minder... Benieuwd wat eruit gaat komen...

Stefkamielkafkajr
Forum actieveling
Forum actieveling
Berichten: 553
Lid geworden op: 25 dec 2013 21:48
waarderingen: 133
Contacteer:

Re: ASIT biotech

Bericht door Stefkamielkafkajr » 14 nov 2019 10:41

Der zal een bav georganiseerd worden daar de helft van het ingelegde kapitaal is opgesoupeerd. Hierbij dienen de aandeelhouders dan te beslissen als ze willen verder gaan met dit bedrijf. Dit is een wettelijke verplichting maw niks bijzonders aan de hand misschien wel een slechte timing
vogelspotter liked last!
Agfa, , Deceuninck , euronav, exmar , acacia pharma,fagron,,transgene, greenyard ,mdxhealt, pharming, , econocom

beursfre
Forum verkenner
Forum verkenner
Berichten: 70
Lid geworden op: 02 mar 2018 15:26
waarderingen: 14
Contacteer:

Re: ASIT biotech

Bericht door beursfre » 14 nov 2019 10:49

hmmm
gisteren tijdig verkocht...
hoop van niet...
Asit, Biocartis, Bone, Exmar, IBA, Inventiva, Mdx

Gebruikersavatar
Naz-T
Forum actieveling
Forum actieveling
Berichten: 797
Lid geworden op: 06 sep 2018 20:48
waarderingen: 320
Contacteer:

Re: ASIT biotech

Bericht door Naz-T » 14 nov 2019 10:51

Agenda:
https://www.asitbiotech.com/investors-m ... er-14-2019

ASIT BioTech
Limited liability company
Having made or making a public appeal on savings
Rue des Chasseurs Ardennais 7 at B-4031 Angleur
VAT BE : 0460.798.795 - RLP Liège
(the « Company »)
CONVENING NOTICE TO THE EXTRAORDINARY GENERAL SHAREHOLDERS’
MEETING
The shareholders, bondholders, subscription right holders, directors and statutory auditors of the Company are
invited to attend the extraordinary general shareholders' meeting of the Company, whose share capital is
currently represented by 20.703.449 voting shares, which will be held on 14 November 2019 at 11 a.m., in
the offices of the notary Tim CARNEWAL (Berquin), 11 Avenue Lloyd George, 1000 Brussels in order to
deliberate and decide on the following agenda :
AGENDA
1. Proposal to anticipate the entry into force of the new Belgian Companies and Associations Code
and to voluntary apply the new Code, pursuant to section 39, §1, sub-paragraph two of the Belgian
Act of 23 March 2019. To this end, proposal to align the articles of association of the Company to
the provisions of the new Code without amending the corporate purpose nor the rights attached to
the shares
Proposed resolution: The general meeting resolves to approve the board of directors’ proposal to
anticipate the entry into force of the new Belgian Companies and Associations Code and to voluntary
apply the new Code, pursuant to section 39, § 1, sub-paragraph two of the Belgian Act of 23 March
2019. As a result, the general meeting resolves to amend the articles of association of the Company to
ensure compliance with the applicable law and in particular with the new Belgian Companies and
Associations Code, An unofficial coordinated version of the new articles of association of the Company
is made available to the shareholders on the website of the Company www.asitbiotech.com, as from 14
October 2019. In this context, the general meeting of shareholders decides to implement the possibility
set forth in section 7:95 of the new Belgian Companies and Associations Code, namely that the
decisions of the board of directors may be adopted by unanimous written resolutions of the directors.
2. Transitional provisions
Proposed resolution: The general meeting decides that, in accordance with section 39, §1, subparagraph two of the Belgian Act of 23 March 2019, the new Belgian Companies and Associations Code
will apply as from the date of publication of the new articles of association of the Company in the
Appendixes to the Belgian Official Gazette. Until this date, the Belgian Companies Code remains fully
applicable to the Company.
3. Confirmation of the cooptation of the director MEUSINVEST SA by NOSHAQ PARTNERS
SCRL, with effect as of 18 December 2018
Proposed resolution: The general meeting resolves to confirm the cooptation of the director
MEUSEINVEST SA by NOSHAQ PARTNERS SCRL, represented by its permanent representative,
Mr. Philippe DEGREER, with effect as of 18 December 2018, decided by the board of directors during
its meeting held on 13 June 2019, for a duration equal to the duration of the director’s mandate of
MEUSEINVEST SA, namely until the ordinary general meeting convened to resolve on the approval
of the annual accounts relating to the financial year ending 31 December 2019.
4. Reading of the special report of the board of directors drafted pursuant to article 633 of the Belgian
Companies Code
2
5. Resolution on the pursuit by the Company of its activity and potential measures to be taken
Proposed resolution: The general meeting resolves based, amongst others, on the aforementioned
report, to continue the Company’s activities. The general meeting acknowledges the measures described by
the board of directors in its report in order to straighten the Company’s financial situation and, in so far as
necessary, approves them.
6. Powers to be granted for the purpose of implementing the foregoing resolutions
Proposed resolution: The general meeting decides to grant full powers to the undersigned notary, acting
alone with the option of substitution, as proxy holder for the purpose of implementing the
abovementioned resolutions, and in particular to proceed with the publications in the Annexes to the
Belgian Official Gazette and to make any modification of the Company’s data at the Crossroads Bank
for Enterprises.
QUORUM AND MAJORITY
Presence quorum: At least 50% of the shares of the Company have to be present or represented at the
shareholders’ meeting in order to validly resolve on items 1 and 2 of the agenda and to vote, as the case may
be, the winding-up of the Company under item 5 on the agenda. If this quorum is not reached, a second general
meeting will be convened with these items on its agenda without there being any specific requirement in terms
of presence quorum for this second meeting. There is no presence quorum requirement for the deliberation and
voting on items 3, 5 (without prejudice of the above) and 7 of the agenda.
Vote and majority:
1. Subject to the applicable legal provisions, each share will carry one vote. Pursuant to article 537
of the Company Code, the bondholders and the holders of subscription rights, have the right to
participate at the general shareholders’ meeting, but with an advisory vote only.
2. The proposed resolutions under items 1 and 2 of the above agenda will be adopted if approved by
three-quarters of the votes. As the case may be, the resolution regarding the winding-up of the
Company under item 5 of the agenda will be adopted by one quarter of the votes validly cast. The
proposed resolutions under items 3, 5 (without prejudice of the above) and 7 of the agenda will be
adopted if approved by simple majority of the votes.
PARTICIPATION TO THE MEETING
Admission requirements
In order to be able to attend the general meeting and exercise the voting rights, in accordance with article 536 §
2 of the Company Code and article 29 of the Company's articles of association, shareholders must comply with
the following conditions:
1. The accounting registration of the shares in the name of the shareholder on 31 October 2019, at midnight
(Belgian time) (the « Record Date »). This registration is established:
• for the registered shares: by way of their registration in the Company’s register of registered
shares;
• for the dematerialized shares: by way of their registration in the accounts of a certified
account holder or a settlement institution.
Only persons who are shareholders on the Record Date will be entitled to participate and vote at the general
meeting.
2. Confirmation of participation: The shareholder must explicitly confirm to the Company his intention to
participate at the general meeting by 8 November 2019 at the latest, by notifying by email to
gregory.nihon@biotech.be, by fax to +32 2 264 03 99 or by letter at the attention of ASIT BioTech SA,
M. Grégory NIHON, 7 rue des Chasseurs Ardennais at 4031 Angleur. For the dematerialized shares, the
certificate(s) issued by the settlement institution or the certified account holder certifying the number of
dematerialized shares registered in the shareholder's name in its accounts on the Record Date, for which the
shareholder declares that he intends to participate at the meeting.
3
3. For the registered shares, the shareholders are accepted at the general meeting on the presentation of their
certificate of registration in the register as long as they have been registered for at least five days at the
meeting.
Participants are invited to arrive on 14 November 2019 as from 10:30 a.m. in order to allow the registration
formalities to proceed efficiently.
Proxies
Any shareholder may be represented at the general meeting by a proxy holder. To do this (i) the shareholder
must appoint this proxy holder using the proxy form established by the Company, which may be obtained on
the Company's website (www.asitbiotech.com) or upon simple request to M. Grégory NIHON at the
Company's registered office or by e-mail to gregory.nihon@biotech.be; (ii) the shareholder is invited to follow
the instructions on the said form and must comply with the registration and confirmation procedure described
above in order to be validly represented at the meeting; (iii) the original of this signed paper form must reach
the Company at the attention of M. Grégory NIHON, 7 rue des Chasseurs Ardennais at 4031 Angleur, at the
latest on 8 November 2019 at 5 p.m. (Belgian time); this form may also be communicated to the Company
within the same period by e-mail to gregory.nihon@biotech.be, by fax to +32 2 264 03 99, as long as the latter
communication is signed by electronic signature in accordance with applicable Belgian law; (iv) any
appointment of a proxy holder must comply with applicable Belgian law, in particular as regards conflicts of
interest and in the keeping of a register.
Available documents
The full text of all documents concerning the general meeting that the law requires to be made available to the
shareholders, directors and statutory auditors and the proposed resolutions will be available on the Company's
website (www.asitbiotech.com) as from 14 October 2019. As from this same date, the shareholders, bondholders
and holders of subscription rights may consult these documents on business days and during normal business
hours at the Company's registered office, 7 rue des Chasseurs Ardennais at 4031 Angleur, and/or, upon
production of their title, obtain free copies of these documents. Requests for copies, free of charge, can also be
sent to M. Grégory NIHON by e-mail to gregory.nihon@biotech.be, by fax to +32 2 264 03 99 or by letter to 7
rue des Chasseurs Ardennais at 4031 Angleur.
RIGHT TO INCLUDE ITEMS ON THE AGENDA
AND TO SUBMIT PROPOSALS FOR DECISIONS
In accordance with article 533ter of the Company Code, one or more shareholders holding together at least
3% of the share capital of the Company may request the inclusion of items on the agenda to be addressed at
the general meeting, and submit proposed resolutions concerning items to be addressed or included on
the agenda. Items to be included on the agenda and/or proposed resolutions must be sent to the Company on
23 October 2019 at the latest by email to gregory.nihon@biotech.be, by fax to +32 2 264 03 99 or by
letter at the attention of M. Gregory NIHON, 7 rue des Chasseurs Ardennais at 4031 Angleur. If applicable,
the Company will publish a completed agenda no later than 30 October 2019. Further information in relation
to the abovementioned rights and the modalities for exercising them are available on the Company’s
website (www.asitbiotech.com).
RIGHT TO ASK QUESTIONS
The shareholders have the right to ask questions in writing to the directors and/or the statutory auditors
prior to the general meeting. These questions can be asked prior to the general meeting by email to
gregory.nihon@biotech.be, by fax to +32 2 264 03 99 or by letter at M. Grégory NIHON, 7 rue des
Chasseurs Ardennais at 4031 Angleur. They must be received by the Company on 8 November 2019 at
5.00 p.m. (Belgian time) at the latest. Further information in relation to the abovementioned right and the
modalities for exercising it are available on the Company’s website (www.asitbiotech.com).
The board of directors.
Stefkamielkafkajr liked last!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 455
Lid geworden op: 30 mei 2018 21:25
waarderingen: 164
Contacteer:

Re: ASIT biotech

Bericht door And its gone! » 14 nov 2019 17:39

Orderboekje kleurt ondertussen bloedrood. Nog eens goed aan de boom schudden?

Info was blijkbaar gekend dat dit ging gebeuren. Dat de kaspositie problematisch was wist iedereen (hopelijk).
Werkingsmiddelen tot Q4 2019.

el_mettos
Forum actieveling
Forum actieveling
Berichten: 683
Lid geworden op: 05 jan 2012 12:58
waarderingen: 171
Contacteer:

Re: ASIT biotech

Bericht door el_mettos » 14 nov 2019 17:55

And its gone! schreef:
14 nov 2019 17:39
Orderboekje kleurt ondertussen bloedrood. Nog eens goed aan de boom schudden?

Info was blijkbaar gekend dat dit ging gebeuren. Dat de kaspositie problematisch was wist iedereen (hopelijk).
Werkingsmiddelen tot Q4 2019.
Op dat orderboekje zou ik niet afgaan. Je moet vooral kijken uit hoeveel versch orders de laat bestaat. 30 000 in de laat, en 7 verkopers. Dat is heus niet bloedrood.
Aan de huidige prijs per aandeel is dat geen massa die door de uitgang wil.

Ik heb het over marktorders uiteraard.
And its gone! liked last!
Als Paul D'Hoore het zegt.... is het al te laat.

Gebruikersavatar
Naz-T
Forum actieveling
Forum actieveling
Berichten: 797
Lid geworden op: 06 sep 2018 20:48
waarderingen: 320
Contacteer:

Re: ASIT biotech

Bericht door Naz-T » 14 nov 2019 18:30

el_mettos schreef:
14 nov 2019 17:55
And its gone! schreef:
14 nov 2019 17:39
Orderboekje kleurt ondertussen bloedrood. Nog eens goed aan de boom schudden?

Info was blijkbaar gekend dat dit ging gebeuren. Dat de kaspositie problematisch was wist iedereen (hopelijk).
Werkingsmiddelen tot Q4 2019.
Op dat orderboekje zou ik niet afgaan. Je moet vooral kijken uit hoeveel versch orders de laat bestaat. 30 000 in de laat, en 7 verkopers. Dat is heus niet bloedrood.
Aan de huidige prijs per aandeel is dat geen massa die door de uitgang wil.

Ik heb het over marktorders uiteraard.
Eerst pb afwachten. Laat zal zich waarschijnlijk gevuld hebben uit onwetendheid van heropening handel. Ik heb ook even getwijfeld om een verkooporder te zetten, maar niet gedaan doordat ik nog op verlies sta en wel tijd had om regelmatig het nieuws te volgen rond heropening.
Kan mij niet inbeelden dat er vandaag iets negatiefs beslist zou zijn geweest. Hopelijk morgenvroeg verder stijgen. Fingers crossed!
el_mettos liked last!

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. 
Registreer binnen enkele tellen



Plaats reactie